查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496018

全球儿科疫苗市场－2024年至2029年预测

Global Pediatric Vaccine Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 130 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

儿科疫苗市场预计将从 2022 年的 309.2 亿美元增至 2029 年的 495.5 亿美元，预测期内复合年增长率为 7.03%。

儿童疫苗接种和免疫接种是先进医疗保健的重要组成部分，儘管许多疫苗很常见，但不同地区的疫苗接种可能略有不同。这些疫苗透过帮助儿童在接触疾病之前培养防御能力和免疫力，帮助保护他们免受各种疾病的侵害。透过加强人体的一般或自然防御，疫苗中所含的抗体使身体能够快速有效地对抗危险的感染疾病。

疫苗是在很小的时候就接种的。儿童的抵抗力和免疫系统对于对抗严重和感染疾病至关重要，但它们仍在发展阶段，增加了感染疾病的风险。这一增长可能是由于公众对疫苗接种重要性的认识不断提高。此外，政府和非政府对疫苗开拓的补贴增加可能会在未来几年进一步发展儿科疫苗产业。

市场驱动因素：

  • 结合疫苗领域的增加预计将推动儿科疫苗的成长。

CDC提案所有 2 岁以下儿童接种肺炎链球菌结合疫苗（PCV13 或 Prevnar13）。

由于免疫反应的改善、儿童极端感染疾病的避免、疫苗接种计划的纳入以及免疫规划的製定，预计联合免疫部分将扩大。由于弱抗原和载体蛋白的结合，结合疫苗对新生儿和幼儿非常有效。它在预防儿童常见的极端感染疾病方面发挥着重要作用，例如 B 型流感嗜血桿菌 (Hib)、肺炎链球菌和脑膜炎奈瑟菌。

由于预防儿童感染疾病的重要性，许多国家已将结合免疫纳入其小儿科免疫计画。世界卫生组织和联合国儿童基金会等组织的全球健康工作和倡议优先考虑儿童健康，并倡导广泛使用抗体。公众意识的提高、进步、政府对研究和开发的支持增加以及改善公共卫生所需的儿童免疫接种的整体优先次序将推动结合疫苗产业的扩张。

  • 政府加大力度改善初级医疗保健基础设施也支持了市场。

不仅在已开发国家，开发中国家也努力提高儿科免疫率，预计将对全球儿科疫苗产业的扩张产生重大影响。此外，儿童流感、百日咳、牙关紧闭、白喉等感染疾病和非感染疾病的流行也是导致该市场快速扩张的主要因素。

此外，由于印度等国家的人口成长，世界各地的儿童数量也在增加。此外，根据联合国儿童基金会2020年的资料，印度每天有67,385名婴儿出生，占世界出生人数的六分之一。因此，新生儿和儿科人口的成长预计将在预测期内推动全球儿科疫苗产业的发展。

北美地区预计将占据全球儿科疫苗市场的很大份额。大规模的研发支出、容易获得最先进的医疗设施、重要的市场竞争对手的存在以及公众对医疗疾病的高度认识被认为是最大的影响因素。

由于加强政府促进医疗保健的政策，预计亚太地区在预测期内将以最高的复合年增长率成长，特别是在印度和中国等成长中的经济体。例如，印度政府有效且成功的脊髓灰质炎疫苗接种计划是该国最成功的儿童疫苗接种计划之一。此外，为了降低儿童死亡率，印度于 2021 年 12 月扩大了肺炎链球菌联合疫苗接种覆盖范围，将 PCV13 疫苗纳入其中。

主要进展：

  • 2024 年 2 月 - Fapon 与印尼国营製药公司 Bio Pharma 签署了一份谅解备忘录，以加强该国的医疗创新。该合作伙伴关係旨在开发生物药品、技术、医疗设备和体外诊断，重点是医疗保健的在地化。其目的是促进协同合作，促进医疗创新，并推动印尼的医疗保健产业。东南亚最大的疫苗製造公司BioPharma将利用两家公司的优势加强医疗服务，为全球诊断和医疗生态系统做出贡献。
  • 2024 年 1 月 - Endeavour Health 透过社区投资基金 (CIF) 向罗莎琳德富兰克林大学的社区护理连结 (CCC) 提供 175 万美元。 CCC 增加了工作人员，将流感疫苗供应增加了一倍，并提供免费健康检查、免疫接种和健康教育计划。 CCC 也租赁了电动车，增加了 COVID-19、链球菌性感染疾病、尿道感染和流感的快速检测套组，并增加了流感疫苗的购买。这种财政支持具有变革性，使 CCC 能够提供更多的健康资源、教育以及与社区机构的联繫，以解决健康的社会决定因素。
  • 2023 年 9 月 -食品药物管理局对辉瑞-BioNTech COVID-19 疫苗（2023-2024）进行了修订。这种单价疫苗针对 SARS-CoV-2 的 omicron 变体 XBB.1.5，已被批准用于 6 个月至 11 岁个体的所有剂量，以预防 COVID-19。它被核准用于尚未接种疫苗的人、已接种一剂辉瑞-BioNTech COVID-19 疫苗的人以及已接种两到四剂辉瑞-BioNTech COVID-19 疫苗的人。
  • 2022 年 6 月 - GSK 获得 FDA核准Priorix，一种麻疹、流行性腮腺炎和德国麻疹疫苗，适用于 12 个月及以上的个体。该疫苗已在 100 多个国家获得批准，迄今已註射了 8 亿多剂疫苗。然而，最近的麻疹疫情爆发可能会逆转几十年来根除麻疹的努力。疾病预防控制中心的研究表明，儿童的免疫记录可能不是最新的，因为订购的疫苗订单减少了，入幼儿园的儿童也减少了。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球儿科疫苗市场：依疫苗类型

  • 介绍
  • 单价
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 多效价的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章全球儿科疫苗市场：依技术分类

  • 介绍
  • 减毒活疫苗
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 灭活疫苗
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 次单位疫苗、重组疫苗、多醣体疫苗、结合疫苗
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 类毒素疫苗
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章 全球儿科疫苗市场：依应用分类

  • 介绍
  • 感染疾病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 癌症
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 过敏
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章全球儿科疫苗市场：按地区

  • 介绍
  • 北美洲
    • 按疫苗类型
    • 依技术
    • 按用途
    • 按国家/地区
  • 南美洲
    • 按疫苗类型
    • 依技术
    • 按用途
    • 按国家/地区
  • 欧洲
    • 按疫苗类型
    • 依技术
    • 按用途
    • 按国家/地区
  • 中东/非洲
    • 按疫苗类型
    • 依技术
    • 按用途
    • 按国家/地区
  • 亚太地区
    • 按疫苗类型
    • 依技术
    • 按用途
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • GlaxoSmithKline Plc
  • Merck Sharp & Dohme Corp.
  • Sanofi
  • Pfizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • AstraZeneca
  • Seqirus（CSL Limited）
简介目录
Product Code: KSI061611923

The global pediatric vaccine market is expected to expand at a CAGR of 7.03% during the projected period to attain US$49.550 billion by 2029, up from US$30.920 billion in 2022.

Vaccination and immunization of children are vital constituents of advanced medication and may change marginally depending upon the area, indeed in spite of the fact that numerous vaccines are common. These vaccines offer assistance to safeguard children from different illnesses by supporting them to grow defense and immunity (assurance) that protects them against illnesses prior to they come into contact with them. By fortifying the human body's common protections i.e. natural defenses, the antibodies in the vaccines allow the human body to battle dangerous infections quickly and more competently.

Vaccines are begun at a very early age. Children are at expanded risk for infectious illnesses since their resistant mechanisms and immune systems are still in the developing phase the essential resistances to battle severe diseases and infections. The boost may be credited to the increasing public awareness among individuals concerning the significance of immunization. An increment in government and non-government subsidizing for the investigation and advancement of vaccines will moreover increase the industry for pediatric vaccines in the years ahead, at the same time, the high price of the vaccine could obstruct the market development in the coming years.

Market Drivers:

  • An increase in the conjugate vaccine segment is anticipated to surge the pediatric vaccine growth.

Conjugate vaccines are chemically attached antigens to carrier proteins, converting them into T-dependent antigens that elicit robust immune responses in infants and adults The CDC suggests the schedule direction for pneumococcal conjugate immunization (PCV13 or Prevnar13) for all children that are under two years of age.

The conjugate immunization segment's extension is anticipated due to improved immune reaction, avoidance of extreme infections in children, incorporated vaccine plans, and development of inoculation programs. Conjugate immunizations are profoundly successful in newborn children and young children because of their weak antigen's combination with a carrier protein. They play a pivotal part in anticipating extreme infectious illnesses commonly influencing children, such as Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, and Neisseria meningitidis.

Numerous nations have consolidated conjugate immunizations into their pediatric immunization plans, reflecting their significance in avoiding infections amid early childhood. Global health well-being activities and initiatives by organizations, like WHO and UNICEF, prioritize health of child and advocate for the broad utilization of antibodies. growing awareness among the public, progressing advancement, in R&D supportive drive by the government, and the general prioritization of pediatric immunization as a necessity for improved public well-being is anticipated to drive expansion within the conjugate vaccine industry.

  • Rising efforts of the government to upgrade their primary healthcare infrastructure would propel the market.

Developing as well as developed nations are taking action to improve admittance to pediatric immunization, which is anticipated to emphatically affect the worldwide pediatric vaccine industry expansion. Besides, the predominance of various infections, such as flu, pertussis, lockjaw, and diphtheria, among other infectious diseases as well as non-infectious diseases in children is however another major cause driving this market exponentially.

Also, the rising populace of nations such as India is expanding up to the population of children all over the globe. Further, as per UNICEF data for 2020, 67,385 babies are born in India each day, which accounts for one-sixth of the world's childbirth. Thus, the rising newborn child and children populace is anticipated to drive the worldwide pediatric vaccine industry amid the projected period.

The global pediatric vaccines market is expected to be dominated by the North American region, which is expected to hold a significant share of the pediatric vaccine market. Large-scale R&D expenditures, easy access to cutting-edge medical facilities, the presence of significant market competitors, and the general public's high degree of medical disease awareness may all contribute to the biggest proportion.

Due to increased government policies to promote healthcare, especially in growing economies like India and China, Asia-Pacific is anticipated to expand at the greatest CAGR over the forecast period. For instance, India's effective and successful polio vaccination drive presented by the government of India is one of the foremost successful pediatric vaccination drives within the nation. Moreover, with the intention to lower childhood mortality, India expanded its Pneumococcal Conjugate immunization scope in December 2021 to incorporate the PCV13 immunization.

Key Development:

  • February 2024- Fapon and Indonesian state-owned pharmaceutical company Bio Farma signed a memorandum of understanding to strengthen medical innovations in the country. The partnership aims to develop biological medicines, technologies, medical devices, and IVD solutions, with a focus on healthcare localization. The goal is to foster synergistic collaboration, drive medical innovation, and boost the healthcare industry in Indonesia. Bio Farma, the largest vaccine manufacturer in Southeast Asia, leverages both companies' strengths to enhance healthcare services and contribute to the global diagnostics and medical treatment ecosystem.
  • January 2024- Endeavor Health provided $1.75 million to Rosalind Franklin University's Community Care Connection (CCC) through its Community Investment Fund (CIF). The CCC has increased staff, doubled flu vaccine availability, and provided free health screenings, vaccinations, and health education programs. The CCC also leased electric vehicles, acquired more rapid-test kits for COVID-19, strep throat, urinary tract infections, and the flu, and increased flu vaccine purchases. The financial support is transformative, enabling the CCC to provide more health resources, education, and connections to community agencies to address social determinants of health.
  • September 2023- The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) was amended by the Food and Drug Administration to include the 2023-2024 formula. The monovalent vaccine, corresponding to the Omicron variant XBB.1.5 of SARS-CoV-2, was authorized for all doses administered to individuals aged 6 months to 11 years to prevent COVID-19. It was approved for unvaccinated individuals, those who have received one dose of any Pfizer BioNTech COVID-19 Vaccine, and those who have received two to four doses.
  • June 2022- GSK received FDA approval for Priorix, a vaccine for measles, mumps, and rubella, for individuals aged 12 months and older. With vaccination licenses in more than 100 countries, more than 800 million doses have been administered. Nevertheless, breakouts in recent times have undone decades of measles eradication. According to CDC research, there has been a decrease in the ordering of vaccines and fewer kids starting kindergarten, which raises the possibility that kids' vaccination records are out of current.

Market Segmentation:

The Global Pediatric Vaccine Market is segmented and analyzed as below:

By Vaccine Type

  • Monovalent
  • Multivalent

By Technology

  • Live-attenuated vaccines
  • Inactivated vaccines
  • Subunit, recombinant, polysaccharide, and conjugate vaccines
  • Toxoid vaccines
  • Others

By Application

  • Infectious Diseases
  • Cancer
  • Allergies

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL PEDIATRIC VACCINE MARKET BY VACCINE TYPE

  • 5.1. Introduction
  • 5.2. Monovalent
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Multivalent
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL PEDIATRIC VACCINE MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Live-attenuated vaccines
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Inactivated vaccines
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Subunit, recombinant, polysaccharide, and conjugate vaccines
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Toxoid vaccines
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL PEDIATRIC VACCINE MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Infectious Diseases
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Cancer
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Allergies
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL PEDIATRIC VACCINE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Vaccine Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Vaccine Type
    • 8.3.2. By Technology
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Vaccine Type
    • 8.4.2. By Technology
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. United Kingdom
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Vaccine Type
    • 8.5.2. By Technology
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. Israel
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Vaccine Type
    • 8.6.2. By Technology
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. Japan
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Indonesia
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Others
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. GlaxoSmithKline Plc
  • 10.2. Merck Sharp & Dohme Corp.
  • 10.3. Sanofi
  • 10.4. Pfizer Inc.
  • 10.5. Serum Institute of India Pvt. Ltd.
  • 10.6. AstraZeneca
  • 10.7. Seqirus (CSL Limited)